© Reuters. FILE PHOTO: A sign at the front entrance to the global headquarters of Illumina is pictured in San Diego, California, U.S., November 28, 2022. REUTERS/Mike Blake/File Photo

(Reuters) – Illumina (NASDAQ:) said on Sunday that it would divest cancer diagnostic test maker Grail.

Original: Stock Market News: Illumina to divest cancer test maker Grail By Reuters